Loading
Among 80 women with triple-negative cancer left at surgery after chemotherapy, a third had ctDNA in their blood; their three-year event-free survival was 48% against 82%, and the blood test added to the pathologist's residual cancer burden score.
End-of-treatment ctDNA was analysed in 80 TNBC patients with residual disease after neoadjuvant systemic therapy in a prospective multisite registry. 33% were ctDNA-positive; residual cancer burden was RCB-I 26%, RCB-II 49%, RCB-III 18%. ctDNA positivity rose with RCB class (14%, 31%, 57%; P 0.028) and was associated with inferior three-year event-free survival (48% versus 82%) and overall survival (50% versus 86%), including within RCB-II (65% versus 87%). RCB class (HR 5.16) and ctDNA status (HR 3.71) were independently prognostic after adjusting for T stage and nodes.
ctDNA and RCB measure different things and both should stratify post-neoadjuvant TNBC trials; an RCB-II patient with negative ctDNA has an 87% three-year event-free survival.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Circulating tumour DNA (ctDNA), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Residual cancer burden (RCB), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Residual cancer burden (RCB), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).
Shares Residual cancer burden (RCB), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Early triple-negative breast cancer.